• Serogroup W135, chocolate agar grew N. meningitidis diseases caused by W135 meningo- after 24 h. (cdc.gov)
  • outbreak because they were genotypi- public of China, all meningococcal An isolate from the cousin of patient cally distinct from the Hajj-related diseases were caused by serogroups 3 was also identifi ed as W135. (cdc.gov)
  • Taiwan (online Technical Appendix), dis serogroup W135 were reported All isolates were susceptible to 12 an- but no direct epidemiologic links in China during 2006-2008. (cdc.gov)
  • Because of the lack of scribe these 3 meningitis patients and ed therapeutic and prophylaxis agents W135 strains from Hajj pilgrimages the N . meningitidis serogroup W135 used frequently in China. (cdc.gov)
  • He became used to characterize the 4 case-related can confi rm that these 3 cases were ill while on a business trip and was W135 N . meningitidis isolates and caused by strains from the same hy- given a diagnosis by culture of an N . other isolates from asymptomatic car- pervirulent clone characterized as meningitidis infection. (cdc.gov)
  • We measured antibodies against Neisseria meningitidis serogroups A, C, Y and W135 in mothers and their 2-month-old infants at study enrollment. (ox.ac.uk)
  • Results: Mothers had low IgG antibodies against serogroups C, W135 and Y polysaccharides, but high serogroup A antibody, whereas 61-78% had protective human complement serum bactericidal activity (hSBA) (≥1:4) for serogroups C, W135 and Y but only 31% for serogroup A. Only 9%, 32%, 45% and 19% of 2-month-old infants had hSBA ≥1:4 for serogroups A, C, W135 and Y, respectively. (ox.ac.uk)
  • An unusual transmission event of Neisseria meningitidis serogroup W135 type 2a in a healthcare setting, England, 2012. (ox.ac.uk)
  • in 2000 and 2001, in association with the hajj, there was an international outbreak of disease caused by a previously rare strain of Neisseria meningitidis, serogroup W135. (who.int)
  • Vaccination is used for close contacts of patients with meningococcal disease due to A, C, Y, or W135 serogroups, to prevent secondary cases. (medscape.com)
  • A single strain (8021) of Neisseria meningitidis , isolated from a child with disseminated meningococcal disease, was found to elaborate two serogroup-specific capsular polysaccharides - Y and W135. (microbiologyresearch.org)
  • Serogroup A Neisseria meningitidis was the major cause of meningococcal meningitis epidemics in the African meningitis belt before 2010 when the monovalent meningococcal A conjugate vaccine (MenAfriVac) was introduced in the region. (springer.com)
  • This study showed the emergence of serogroup X, a non-vaccine type, as the predominant N. meningitidis serogroup in the wake of a declining serogroup W in Ghana's meningitis belt. (springer.com)
  • A potential cause of this shift is the fact that the polysaccharide capsule based vaccine formulated for serogroups A, C, W-135 and Y is ineffective against children under 2 years of age and has only been useful for outbreaks of the disease. (loinc.org)
  • Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. (wikipedia.org)
  • Nimenrix (developed by GlaxoSmithKline and later acquired by Pfizer), is a quadrivalent conjugate vaccine against serogroups A, C, W-135, and Y. In April 2012 Nimenrix was approved as the first quadrivalent vaccine against invasive meningococcal disease to be administered as a single dose in those over the age of one year, by the European Medicines Agency. (wikipedia.org)
  • Bivalent rLP2086 is a recombinant factor H binding protein-based vaccine approved in the USA for prevention of meningococcal serogroup B disease in 10-25-year-olds. (nih.gov)
  • Immunogenicity was determined in serum bactericidal antibody assay using human complement (hSBA) by use of four meningococcal serogroup B test strains expressing vaccine-heterologous factor H binding protein variants: PMB80 (A22), PMB2001 (A56), PMB2948 (B24), and PMB2707 (B44). (nih.gov)
  • AIM: We measured meningococcal serogroup C (MenC)-specific memory B-cell responses in infants by Enzyme-Linked Immunospot (ELISpot) following different MenC conjugate vaccine schedules to investigate the impact of priming on immune memory. (ox.ac.uk)
  • A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. (ox.ac.uk)
  • We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. (ox.ac.uk)
  • Nowadays, after our country introduced meningococcal serogroup A vaccine, we have seen a reduction in these major epidemics. (cdc.gov)
  • Bexsero is a vaccine used to protect individuals from the age of two months against invasive meningococcal disease caused by one group of the bacterium Neisseria meningitidis (group B). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood infection). (europa.eu)
  • The meningococcal vaccine protects against infections caused by the bacteria Neisseria meningitidis (meningococci). (msdmanuals.com)
  • The conjugate vaccine (MCV4, protecting against serogroups A, C, W, and Y) is preferred for people 9 months to 55 years old and is used for routine childhood vaccination (see CDC: Meningococcal ACWY vaccine information statement ). (msdmanuals.com)
  • If approved and recommended, MenABCWY could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine. (biospace.com)
  • MenHibrix, a combination vaccine, is a 4-dose sequence approved for use in children as young as 6 weeks old and is indicated for active immunity against invasive disease caused by Neisseria meningitides serogroups C and Y, and Haemophilus influenzae type b. (medscape.com)
  • In October 2014, the FDA approved the first meningococcal vaccine for serogroup B (Trumenba) under the breakthrough therapy designation and accelerated approval regulatory pathways. (medscape.com)
  • Meningococcal Group B Vaccine is used to prevent disease caused by Neisseria meningitidis serogroup B. (rxwiki.com)
  • Meningococcal Group B Vaccine helps to protect against Neisseria meningitidis which is a leading cause of bacterial meningitis. (rxwiki.com)
  • Meningococcal Group B Vaccine is used to prevent disease caused by Neisseria meningitidis serogroup B in individuals aged 10 through 25 years of age. (rxwiki.com)
  • On October 29, 2014, a new vaccine against invasive meningococcal disease caused by Neisseria meningitidis serogroup B was licensed by the Food and Drug Administration. (chop.edu)
  • While all adolescents are currently recommended to receive the current meningococcal vaccines (either Menactra® or Menveo®), the new serogroup B vaccine, Trumenba®, offers an opportunity to protect against the type of meningococcal infection that was recently diagnosed on the campuses of Princeton University and University of California, Santa Barbara. (chop.edu)
  • The MenACWY-CRM vaccine (Menveo) is indicated for protection against serogroups A, C, W, and Y of Neisseria meningitidis in people ages two months through 55 years. (medpagetoday.com)
  • This vaccine helps reduce the risk of developing Neisseria meningitidis infection, which may lead to diverse complications including meningitis, bacteremia, and pneumonia. (pharmacytimes.com)
  • 4 Despite the fact that serogroup B meningitis affects children disproportionately, currently, no vaccine is available in the United States that protects patients against serogroup B, which may be why the meningococcal vaccine is only recommended in selected groups of very young children. (pharmacytimes.com)
  • All but 1 of these vaccines is quadrivalent, meaning that each vaccine provides protection against serogroups A, C, W, and Y. The single exception is MenHibrix, which only offers protection against serogroups C and Y. However, unlike the other vaccines, MenHibrix may be used in children as young as 6 weeks (as a 4-dose series). (pharmacytimes.com)
  • The FDA has approved the first U.S. vaccine against invasive meningococcal disease caused by Neisseria meningitides serogroup B. Trumenba is approved for use in individuals aged 10 through 25 years. (medscape.com)
  • Approval was based on three randomized studies in about 2800 adolescents, in which 82% of subjects given three doses of the vaccine developed antibodies against four different N meningitidis serogroup B strains representative of those that cause serogroup B meningococcal disease in the United States, compared with less than 1% prior to vaccination. (medscape.com)
  • A variety of routine childhood and adolescent meningococcal vaccination programs using monovalent (serogroup C) and quadrivalent (A, C, Y, W) conjugate vaccines have been implemented in Canada since 2002, resulting in a decrease in invasive meningococcal disease (IMD) incidence, particularly in serogroup C. Meningococcal vaccines have also been used for outbreak response, including the multicomponent vaccine serogroup B vaccine. (canada.ca)
  • Invasive meningococcal disease caused by some serogroups is vaccine preventable and endemic in Canada, with increased activity occurring periodically in the winter months. (canada.ca)
  • This has resulted in a decrease in IMD incidence, particularly for serogroup C. In the last decade, the multicomponent meningococcal B vaccine (4CMenB) has been used to control outbreaks Footnote 3 but has not been used in routine vaccination programs across the country. (canada.ca)
  • Additionally, as of 2009, Men-C ( Neisseria meningitidis -Serogroup C) vaccine has been added to the 12 month vaccination schedule. (umanitoba.ca)
  • The aim of this work was to determine the meningococcal serogroups in Burkina Faso despite the vaccine pressure. (santetropicale.com)
  • Cerebrospinal meningitis remains a burden and non-vaccine serogroups have taken place in epidemics in Burkina Faso. (santetropicale.com)
  • Immunogenicity and safety of the vaccine were assessed in 6300 individuals who received a single dose of MenQuadfi, which showed a good safety profile and induced a high immune response against all four Neisseria meningitidis serogroups. (pharmtech.com)
  • After the introduction of meningococcal A vaccines in 2013, meningitis caused by serogroup A declined. (cdc.gov)
  • Expanding availability of multivalent vaccines that are effective against non-A serogroups of N. meningitidis might prevent future outbreaks in this region. (cdc.gov)
  • Among 1,339 cases with laboratory testing, 433 (32%) were positive for bacterial pathogens, including 358 (82.7%) confirmed cases of Neisseria meningitidis serogroup C. In response, approximately 2.1 million persons aged 2-29 years were vaccinated with meningococcal serogroup C-containing vaccines in Katsina, Sokoto, Yobe, and Zamfara states during April-May 2017. (cdc.gov)
  • Recent vaccines for serogroups A and C have proven to be more effective in that age group which has led to serogroup Y being the most likely cause of pneumonia from Neisseria meningitidis. (loinc.org)
  • Immunizing mothers before or during pregnancy with meningococcal conjugate vaccines might increase antibody levels in early infancy and provide protection against infection due to N. meningitidis. (ox.ac.uk)
  • There are three vaccines available in the United States to prevent meningococcal disease, all quadrivalent in nature, targeting serogroups A, C, W-135, and Y: three conjugate vaccines (MCV-4), Menactra, Menveo and MenQuadfi. (wikipedia.org)
  • Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial. (ox.ac.uk)
  • [ 17 ] Current meningococcal vaccines are indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis . (medscape.com)
  • The use of meningococcal vaccines that include coverage against serogroups W and Y in immunization programs for older adults needs to be evaluated to inform health authorities' decisions of the relative benefits of vaccination and the utility of expanding national immunization programmes to this age group. (biomedcentral.com)
  • Previously, meningococcal vaccines licensed for use in the U.S. only covered four of the five main serogroups of bacteria that cause meningococcal disease: A, C, W and Y. (chop.edu)
  • Earlier approved vaccines only covered four of the five primary serogroups of N meningitidis . (medscape.com)
  • Serogroup W associated with ST-11 CC is becoming a growing contributor of disease in all age groups not protected by serogroup W-containing vaccines. (canada.ca)
  • Since the early 2000s, a variety of routine childhood and adolescent vaccination programs using monovalent (serogroup C) and quadravalent (serogroup A, C, Y and W-135) meningococcal conjugate vaccines have been implemented in Canada Footnote 3 . (canada.ca)
  • Both enzymes are necessary for survival of N. meningitidis under oxidative stress and during bloodstream infection. (rcsb.org)
  • Objectives To evaluate and characterise meningococcal carriage among healthy men who have sex with men (MSM) within a screening programme for Neisseria gonorrhoeae infection at the San Gallicano Dermatological Institute, Italy. (bmj.com)
  • Determining serotype for Haemophilus influenzae (Hi) and serogroup for Neisseria meningitidis (Nm) is crucial for identifying potential outbreaks and determining appropriate public health responses. (cdc.gov)
  • These components are the Haemophilus influenzae type b capsular polysaccharide [polyribosylribitol phosphate (PRP)] that is covalently bound to an outer membrane protein complex (OMPC) of Neisseria meningitidis and hepatitis B surface antigen (HBsAg) from recombinant yeast cultures. (theodora.com)
  • Haemophilus influenzae type b and Neisseria meningitidis serogroup B are grown in complex fermentation media. (theodora.com)
  • The primary ingredients of the phenol-inactivated fermentation medium for Haemophilus influenzae include an extract of yeast, nicotinamide adenine dinucleotide, hemin chloride, soy peptone, dextrose, and mineral salts and for Neisseria meningitidis include an extract of yeast, amino acids and mineral salts. (theodora.com)
  • The PRP-OMPC conjugate is prepared by the chemical coupling of the highly purified PRP (polyribosylribitol phosphate) of Haemophilus influenzae type b (Haemophilus b, Ross strain) to an OMPC of the B11 strain of Neisseria meningitidis serogroup B. The coupling of the PRP to the OMPC is necessary for enhanced immunogenicity of the PRP. (theodora.com)
  • Three main bacterial species are responsible for causing meningitis, Streptococcus pneumoniae (Sp), Haemophilus influenzae type b (Hib) and Neisseria meningitidis (Nm) most likely to cause major epidemics of cerebrospinal meningitis (CSM) [ 3 ]. (biomedcentral.com)
  • Haemophilus influenzae type b, Streptococcus pneumoniae , and Neisseria meningitidis colonise the mucosa of the human upper respiratory tract along with other opportunistic pathogens and commensal bacteria. (bmj.com)
  • La fréquence des MBA était de 21,70% (156/719), avec Streptococcus pneumoniae en tête 44,88% (70/156) suivi de Neisseria meningitidis 42,94% (67/156) et Haemophilus influenzae 12,18% (19/156). (santetropicale.com)
  • The frequency of ABM was 21.70% (156/719), with Streptococcus pneumoniae leading 44.88% (70/156), follow by Neisseria meningitis 42.94% (67/156) and Haemophillus influenzae 12.18% (19/156). (santetropicale.com)
  • CusabioAlternative Name(s): /Gene Names: ihfBResearch Areas: TranscriptionOrganism: Neisseria meningitidis serogroup B (strain MC58)AA. (joplink.net)
  • Here, we report the genome sequence of N. meningitidis strain LNP27256, an isolate of sequence type 11 linked to a recent outbreak among men who have sex with men in Europe. (pasteur.fr)
  • We previously showed that a strain type belonging to sequence type 23 was responsible for the increased prevalence of this serogroup in Sweden. (ox.ac.uk)
  • However, in recent years, there continues to be the threat of meningococcal disease due to other serogroups such as C, W and X. This year our concern has focused on the first outbreak in Burkina Faso due to a strain of serogroup C that previously caused large epidemics in neighboring Niger and Nigeria. (cdc.gov)
  • The NMB0736 gene of Neisseria meningitidis serogroup B strain MC58 encodes the putative nitrogen regulatory protein, IIANtr (abbreviated to NM-IIANtr). (rcsb.org)
  • The N. meningitidis strains isolated were sensitive to penicillin, chloramphenicol, erythromycin, streptomycin, kanamycin, MIC of sulphadiazine of 3 strains were 6.4 mgm,/L while of 1 strain was 10 mgm/L i.e. all 4 strains were partially resistant to sulphadiazine. (jpgmonline.com)
  • Of the 14 cases among persons with HIV in 2022 that were not related to the outbreak primarily among MSM, nine were caused by a single strain of N. meningitidis serogroup Y clonal complex CC174 sequence type ST-1466. (medscape.com)
  • Draft Genome Sequence of a Neisseria meningitidis Serogroup C Isolate of Sequence Type 11 Linked to an Outbreak among Men Who Have Sex with Men. (pasteur.fr)
  • In the report " Rapid Laboratory Identification of Neisseria meningitidis Serogroup C as the Cause of an Outbreak - Liberia, 2017, " on page 1145, the figure title was not included in the printed version of this report. (cdc.gov)
  • Journal of Postgraduate Medicine: Outbreak of meningitis due to Neisseria meningitidis--a microbiological profile. (jpgmonline.com)
  • gococcal outbreak among hajj pilgrims, which was caused by Neisseria meningitidis serogroup A, was reported in 1987 and the Methods disease spread quickly to all countries [ 1 ]. (who.int)
  • Genome-Based Characterization of Emergent Invasive Neisseria meningitidis Serogroup Y Isolates in Sweden from 1995 to 2012. (ox.ac.uk)
  • Whole-genome sequencing was performed on invasive serogroup Y isolates from 1995 to 2012 in Sweden (n = 186). (ox.ac.uk)
  • These isolates were compared to a collection of serogroup Y isolates from England, Wales, and Northern Ireland from 2010 to 2012 (n = 143), which had relatively low serogroup Y incidence, and two isolates obtained in 1999 in the United States, where serogroup Y remains one of the major causes of IMD. (ox.ac.uk)
  • The isolates of Neisseria meningitidis recovered from the throat cultures were serogrouped, serotyped, and assigned to a clone on the basis of an analysis of the electrophoretic mobilities of 14 metabolic enzymes. (cambridge.org)
  • N. meningitidis isolates were evaluated for antibiotic susceptibility and characterised by whole genome sequencing. (bmj.com)
  • Forty-three viable N. meningitidis isolates were cultivated (42 from pharyngeal and 1 from rectal swabs). (bmj.com)
  • Isolates are characterized using whole genome sequencing to determine serogroup and molecular typing information. (medscape.com)
  • Isolates were sent to the National Microbiology Laboratory for confirmation of serogroup and further studies including phenotype and clonal complex identification. (canada.ca)
  • Prior to 2015, most invasive serogroup W isolates were identified as clonal complex 22 (ST-22 CC) and the increase in serogroup W in Canada in recent years has been associated with the replacement of the endemic ST-22 CC with the hyper-virulent ST-11 CC. (canada.ca)
  • The objective of this study was to investigate the serogroup Y emergence by whole-genome sequencing and compare the meningococcal population structure of Swedish invasive serogroup Y strains to those of other countries with different IMD incidence. (ox.ac.uk)
  • We identified that older adults with IMD were mainly affected by serogroups W and Y, which are generally not the predominant strains in circulation in most countries. (biomedcentral.com)
  • glucose, maltose and lactose, an oxidase test was performed and the strains were streaked onto nutrient agar plates which were incubated at 22 C. The strains, which were oxidase positive, fermented only glucose and maltose, failed to grow on nutrient agar plate at 22 C, were reported as Neisseria meningitidis. (jpgmonline.com)
  • Bexsero contains parts of the bacteria N. meningitidis group B. (europa.eu)
  • Two main studies showed that Bexsero was effective at stimulating an immune response to N. meningitidis group B. The studies measured the production of protective antibodies which are able to kill the bacteria. (europa.eu)
  • N. meningitidis is transmitted from person to person, and close contact with a healthy carrier can facilitate the spread of the bacteria to susceptible individuals. (bmj.com)
  • It has long been recognised that serum antibodies to capsular PS of some bacteria including H influenzae type b, S pneumoniae , and N meningitidis are protective against invasive disease. (bmj.com)
  • The identification of bacteria responsible for Acute Bacterial Meningitis (ABM) as well as the serogrouping of Neisseria meningitidis species were achieved by real-time PRC (rtPCR). (santetropicale.com)
  • The 3 cases we report were ob- serogroups of this organism. (cdc.gov)
  • Transferrin-binding protein 1Gene Names: tbp1Research Areas: Cell BiologyOrganism: Neisseria. (joplink.net)
  • CusabioAlternative Name(s): Class 3 protein PorinGene Names: porBResearch Areas: Signal TransductionOrganism: Neisseria meningitidis serogroup BAA. (joplink.net)
  • Several protein carriers have been used including tetanus toxoid (TT), diphtheria toxoid, mutant diphtheria toxin (CRM197), and the outer membrane protein of N meningitidis . (bmj.com)
  • However, N. meningitidis serogroup C (NmC) has now emerged as a cause of large outbreaks. (cdc.gov)
  • Detecting serotype and serogroup are important for identifying potential outbreaks and determining appropriate public health responses. (cdc.gov)
  • Before 2010, Neisseria meningitidis A ( NmA ) was the leading cause of meningitis epidemics, accounting for almost 90% of outbreaks. (who.int)
  • Recent outbreaks of serogroup B meningococcal disease on a few college campuses have heightened concerns for this potentially deadly disease. (medscape.com)
  • Neisseria meningitidis employs polysaccharides and outer membrane proteins to cope with human serum complement attack. (uni-wuerzburg.de)
  • Neisseria menin- provincial Centers for Disease Control ported to cause invasive disease in gitidis is a gram-negative bacterium and Prevention (CDC) in China and Taiwan during 1996-2002 and were found only in humans and is a major confi rmed at the Chinese CDC. (cdc.gov)
  • Bexsero contains four proteins which are found on the surfaces of cells of the N. meningitidis group B bacterium. (europa.eu)
  • Neisseria meningitidis is an encapsulated Gram-negative diplococcus that asymptomatically colonises the upper respiratory tract in up to 25% of the population (mainly adolescents and young adults). (biomedcentral.com)
  • With global environmental changes and massive vaccination targeting a unique serogroup, an epidemiological transition of bacterial meningitis is ongoing, requiring both a better consideration of the etiological nature of the responsible agents and of their proximal and distal determinants. (biomedcentral.com)
  • Epidemics of meningitis due to N. meningitidis are a serious medical emergency with both public health and socioeconomic implications. (springer.com)
  • Epidemics of meningitis due to N. meningitidis are often difficult to predict, leading to delayed initiation of control measures, such as immunisation, resulting in poor outcomes. (springer.com)
  • At presentation, meningitis due to N meningitidis may be impossible to differentiate from other types of meningitis. (medscape.com)
  • In our study, we could detect only 4 cases by smear and culture though all 14 cases were detected using Wellcogen latex agglutination kits, thereby highlighting the vital role of immunological studies in the rapid diagnosis of meningitis due to N. meningitidis. (jpgmonline.com)
  • Among the cases of meningitis due to Neisseria meningitidis, only serogroups C and X were detected with 68.65% (46/67) and 31.35% (21/67) respectively. (santetropicale.com)
  • Humans are the only hosts of N. meningitidis and can carry them harmlessly in the pharynx. (bmj.com)
  • N. meningitidis was first identified in 1884 [ 3 ] and isolated from patients with CSM by Weichsel Baum in Vienna in 1887 as a gram-negative diplococcus. (springer.com)
  • Neisseria meningitidis (Gram-negative diplococcus) is responsible globally for invasive meningococcal disease (IMD), in particular septicaemia and meningitis. (bmj.com)
  • Most patients with meningococcal meningitis, caused by the gram-negative diplococcus Neisseria meningitidis , recover completely if appropriate antibiotic therapy is instituted promptly. (medscape.com)
  • Therefore, this study aimed to establish the trends in N. meningitidis serogroups from 2016 to 2020 in Ghana's meningitis belt. (springer.com)
  • Meningococcal disease caused by Neisseria meningitidis causes severe illness, and could lead to permanent disability or death if not quickly detected and treated. (cdc.gov)
  • The largest global burden of meningococcal disease is in sub-Saharan Africa, where annual epidemics caused mainly by N. meningitidis serogroup A were previously common. (cdc.gov)
  • Cerebrospinal meningitis (CSM) caused by N. meningitidis is a contagious disease. (springer.com)
  • https://www.cdc.gov/meningitis/lab-manual/chpt10-pcr.html] There has been a large increase in the proportion of meningococcal disease caused by N. meningitidis serogroup Y since 1989. (loinc.org)
  • Invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup Y has increased in Europe, especially in Scandinavia. (ox.ac.uk)
  • In Sweden, serogroup Y is now the dominating serogroup, and in 2012, the serogroup Y disease incidence was 0.46/100,000 population. (ox.ac.uk)
  • Future genome-wide association studies are needed to reveal additional genes associated with serogroup Y meningococcal disease, and this work would benefit from a complete serogroup Y meningococcal reference genome. (ox.ac.uk)
  • In December 2022, Pfizer announced that the FDA had accepted for review a BLA for its MenABCWY candidate for the prevention of meningococcal disease caused by the most common serogroups in individuals 10 through 25 years of age. (biospace.com)
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age. (fda.gov)
  • Serogroup B continues to account for the greatest proportion of disease. (canada.ca)
  • In Europe, there were more than 3000 cases of Invasive Meningococcal Disease in 2018, half of them caused by serogroups C, W, and Y," said Thomas Triomphe, head of Sanofi Pasteur, in the press release. (pharmtech.com)
  • Disease due to serogroup W-135 Neisseria meningitidis. (microbiologyresearch.org)
  • Since 2000, other Nm serogroups including W, X and C have also been responsible for causing epidemics. (biomedcentral.com)
  • However, serogroup W also causes endemic diseases in some African meningitis belt countries. (springer.com)
  • Menveo does not prevent N eisseria meningitidis serogroup B infections. (gsk.com)
  • Neisseria meningitidis has 13 clinically significant serogroups, classified according to the antigenic structure of their polysaccharide capsule. (wikipedia.org)
  • ABSTRACT We determined the carriage rate of Neisseria meningitidis before and after hajj pilgrimage among a group (1) of 674 randomly selected Iranian pilgrims, and the effect of 500 mg of ciprofloxacin given 24 hours before return on the reduction of meningococcal carriers among another group (2) of 123 randomly selected Iranian pilgrims. (who.int)
  • Conclusions Serogroup B meningococcal carriage identified from oral and anal specimens among healthy MSM was the most frequent serogroup identified in this study. (bmj.com)
  • Conclusions: The levels of serogroup-specific meningococcal antibodies were low in mothers and 2-month-old infants. (ox.ac.uk)
  • The study showed that Bexsero was effective at stimulating an immune response to N. meningitidis group B. In addition, a single booster dose of Bexsero at 12 months of age produced a stronger immune response in children who had already received Bexsero than the first of two 'catch-up' doses in children of the same age who had not. (europa.eu)
  • The study showed that Bexsero was effective at stimulating an immune response to N. meningitidis group B and that two doses were needed to produce an adequate immune response. (europa.eu)
  • Bexsero has been shown to produce a robust immune response to N. meningitidis group B and the risks are acceptable. (europa.eu)
  • ; Neisseria meningitidis serogroup W ( NmW ) and Hemophilus influenzae type b ( Hib ). (who.int)
  • Neisseria meningitidis serogroup A was detected by latex test. (health.gov.au)